| Identification | Back Directory | [Name]
2H-1,4-Benzoxazine-8-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-chloro-3,4-dihydro-4-methyl-3-oxo-, benzenesulfonate (1:1) | [CAS]
2025360-91-0 | [Synonyms]
arazasetron (SENS-401)
(R)-Azasetron besylate | [Molecular Formula]
C17H20ClN3O3.C6H6O3S | [MOL File]
2025360-91-0.mol | [Molecular Weight]
507.99 |
| Hazard Information | Back Directory | [Uses]
(R)-Azasetron besylate (SENS-401) is an orally active calcineurin inhibitor. (R)-Azasetron besylate reduces Cisplatin (HY-17394)-induced hearing loss and cochlear damage[1][2]. | [References]
[1] Petremann M, et al. SENS-401 Effectively Reduces Severe Acoustic Trauma-Induced Hearing Loss in Male Rats With Twice Daily Administration Delayed up to 96?hours. Otol Neurotol. 2019 Feb;40(2):254-263. DOI:10.1097/MAO.0000000000002088
[2] Petremann M, et al. Oral Administration of Clinical Stage Drug Candidate SENS-401 Effectively Reduces Cisplatin-induced Hearing Loss in Rats. Otol Neurotol. 2017 Oct;38(9):1355-1361. DOI:10.1097/MAO.0000000000001546 |
|
|